Company Profile
Unicycive Therapeutics Stock Price, News & Analysis
Company overview
Business overview
Unicycive Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Unicycive Therapeutics is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Business Model Characteristics
Unicycive Therapeutics follows a pipeline-led model where clinical readouts, filing updates, and program expansion determine how the market underwrites the story.
Position Within the Biotechnology Landscape
Compared with more mature healthcare names, Unicycive Therapeutics sits on the development side of the biotech landscape, where catalyst timing can reprice the stock quickly.
Why the stock is moving
UNCY is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
Unicycive’s catalysts are oxylanthanum carbonate and the CKD-phosphate-binder program, where regulatory progress matters most. The company still needs a clean approval path.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
- 02
Unicycive Therapeutics to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference
Source: Unicycive Therapeutics
- 03
Unicycive Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update
Source: Unicycive Therapeutics
- 04
Unicycive Therapeutics to Participate in Upcoming Investor Events in December
Source: Unicycive Therapeutics
- 05
Unicycive Therapeutics Announces Resubmission of New Drug Application (NDA) for Oxylanthanum Carbonate (OLC)
Source: Unicycive Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.